Amar S. Naik MDAssociate Professor of Medicine; Director, Inflammatory Bowel Disease Program; Regional Medical Director, Nutrition Services, Division of Gastroenterology, Loyola University Medical Center, Maywood, Illinois
Amar Naik is a board-certified gastroenterologist and medical director of the Inflammatory Bowel Disease program and regional medical director of Nutrition services at Loyola Medicine in Chicago, IL. He graduated from the University of Illinois College of Medicine at Chicago, and his postgraduate training was in Milwaukee at the Medical College of Wisconsin. Dr. Naik is an active member of the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, and the Crohn’s and Colitis Foundation. He is devoted to multifaceted aspects of IBD patients’ care through development of a multidisciplinary academic clinical program to *Improve access to high quality care, *Maintain longterm treatment efficacy with high health related quality of life, and *Perform research with a goal to improve IBD treatment outcomes in unique patient populations. Dr. Naik has presented his research in international GI meetings as well as published in peer-reviewed journals in the field of Gastroenterology. Additionally, he has a special interest in IBD education, with involvement in the gastroenterology fellowship training program as well as patient education programs.
DisclosuresDr. Naik is on the speakers' bureaus for Abbvie, Takeda, Pfizer, and Bristol Meyers Squibb.
Recent Contributions to PracticeUpdate:
- Scoring System to Determine Colectomy Risk for Patients With Acute Severe Ulcerative Colitis
- Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease
- Association Between Statin Use and Inflammatory Bowel Diseases
- Adalimumab Treatment After Complete Resolution of Sepsis and Abscess in Patients With Crohn's Disease
- Discontinuation of Infliximab and Risk of Relapse in Patients With Sustained Complete Remission of Crohn’s Disease
- Patient Outcomes With Early vs Late Use of Vedolizumab in Ulcerative Colitis
- Head-to-Head Comparison of Ustekinumab and Adalimumab in the Treatment of Moderate to Severe Crohn's Disease
- Discontinuing Infliximab in Patients With Ulcerative Colitis in Remission
- Deep Neural Network Accurately Predicts Prognosis of Ulcerative Colitis Using Endoscopic Images
- Risk of Venous Thromboembolism After Hospital Discharge in Patients With IBD